News

Sarepta Makes Big Cuts After Patient Deaths. Its Prospects Remain Uncertain.
The pharma company said it would lay off a third of its workforce and add a black-box warning to its controversial gene ...
BioSpace3h
Sarepta Up 18% After Business Overhaul as Analysts Cautiously Optimistic
Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...
Here's Why Sarepta Stock Is Jumping Thursday
Shares of drug developer Sarepta Therapeutics surged more than 20% in morning trading, rising after the late-Wednesday news ...
Sarepta: Finally, A Little Relief For Bulls; I Expect More
Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...
BioPharma Dive21h
Sarepta to lay off about 500 employees after Duchenne gene therapy setbacks
The company is also pausing research for several treatments it has been developing for another form of muscular dystrophy.
GEN - Genetic Engineering and Biotechnology News15h
Sarepta Axes 500, 36% of Workforce, in Restructuring after DMD Patient Deaths
Sarepta Therapeutics said it will eliminate 36% of its workforce—approximately 500 jobs—in a restructuring that follows the ...
STAT4h
Pharmalittle: We’re reading about a Bristol-Pfizer direct-to-consumer sales plan, Sarepta layoffs, and more
Report found business relationships between telehealth and pharma companies may indirectly lead patients toward certain ...
Sarepta Stock Soars 30%. Why Layoffs and a ‘Black-Box’ Warning Are Good News.
Sarepta Therapeutics stock soared over 30% after the pharmaceutical company said it would lay off about 500 employees. It ...